GSK plc Stock
Price
Target price
€16.29
€16.29
-0.180%
-0.03
-0.180%
-
03.07.25 / Tradegate
WKN: A3DMB5 / Symbol: GLAXF / Name: GSK / Stock / Pharmaceuticals / Large Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
GSK plc Stock
The price for the GSK plc stock decreased slightly today. Compared to yesterday there is a change of -€0.030 (-0.180%).
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for GSK plc stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of GSK plc in the next few years
Pros
?
C******** o* t** e**********
?
S********** s********
?
B****
Cons
?
G***** c******* t* c**********
?
M***** P*******
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of GSK plc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| GSK plc | -0.180% | -1.333% | -8.944% | -8.816% | -0.306% | -22.151% | -10.099% |
| AstraZeneca plc | 0.290% | -0.374% | -4.958% | -16.194% | -5.818% | -4.921% | 23.863% |
| Johnson & Johnson | 0.820% | 2.140% | -2.297% | -1.733% | -4.587% | -22.912% | 5.317% |
| Elanco Animal Health Inc. | 0.190% | 2.030% | 5.218% | -4.885% | 7.915% | -33.458% | -34.063% |
Comments
GSK's looking like a pretty sweet deal right now! They've just bumped up their long-term sales outlook to over £40 billion by 2031, which is music to my ears. Plus, they're planning a £2 billion share buyback - talk about putting their money where their mouth is! Their recent earnings were better than expected, and they're making some exciting moves in oncology. Sure, there's some vaccine sales hiccups, but their specialty medicines are picking up the slack. With a price-to-earnings ratio of just 8x, it seems like the market's not giving GSK enough credit for its potential. It's like finding a hidden gem in your grandma's attic - there's a lot more value here than meets the eye. The pipeline looks promising, and if their bets on cancer drugs pay off, we could see this stock soar. It's not without risks, but at this price, I reckon it's worth a punt. GSK might just be the dark horse in the pharma race!
Show more
Hey there! I've been keeping an eye on GSK, and I've got to say, things aren't looking too rosy right now. Their stock just hit a 10-month low, which is like watching your favorite sports team lose a crucial game. The big issue? Their RSV and shingles vaccines aren't performing as well as expected, especially in the U.S. market. It's like they've got a star player who's suddenly lost their mojo. While their HIV and cancer treatments are showing some promise, it's not enough to offset the vaccine sales slump. The company's trying to put on a brave face by sticking to their full-year guidance, but I'm not entirely convinced. It's like they're saying 'This is fine' while the room's on fire. Given the current situation, I think we might see the stock price dip further before it starts to recover. It's a bit like watching a rollercoaster – we're on the downward slope right now, and it might be a while before we start climbing again. Keep an eye on how they address these vaccine challenges in the coming months – that'll be key to any potential turnaround.
Show more
